Wednesday, April 17, 2024
HomeRecent ArticlesClinChoice Acquires Clinical Research Organisation CSI

ClinChoice Acquires Clinical Research Organisation CSI

ClinChoice is a full-service global Clinical Research Organisation announced the acquisition of CSI Medical Research (CSI).Through this strategic acquisition, ClinChoice further broadens its global footprint and full-service capabilities in more than 30 countries throughout Asia, Europe and North America around the world.

ClinChoice is a full-service global Clinical Research Organisation announced the acquisition of CSI Medical Research (CSI). Through this strategic acquisition, ClinChoice further broadens its global footprint and full-service capabilities in more than 30 countries throughout Asia, Europe and North America around the world.

Read also – Vintage Investment Partners Closes 4th Growth-Stage Venture Fund at $200 Mn

CSI Medical Research is Singapore based and registered Clinical Research Organisation (CRO) with intent to provide clinical trials related service offerings to our customers. CSI Medical Research (CSI MR) have extensive and applicable local knowledge of key workflows both in investigator’s sites and from sponsors. Given the Singapore’s government huge endorsement on clinical research, both in resources and financial support. CSI MR aims to answer this call to support these important segments and is determined to utilize our industry experience to provide good quality, customized and cost effective services.

Read also – Dubai-based eesee Raises $2.85 Mn Funding

“This is an exciting time for ClinChoice, and we are thrilled to welcome the talented CSI team to the ClinChoice family.” said Mr. Ling Zhen, Global Chairman and CEO of ClinChoice, “With their wide-range of highly valuable service offering and seasoned professional team, the acquisition of CSI will further expand our presence in SEA and ANZ, and enhance our capability to well fulfill our clients’ need locally and globally.”

Read also – Akshayakalpa Organic Secures Approximately $12 Mn Series C Funding

“Joining with ClinChoice is the ideal next chapter in CSI growth story. We are excited to leverage on our familiarity with the SEA and ANZ regulations as well as the clinical sites within a region we called home, to assist more customers to navigate through the challenges with great speed and better cost efficiencies.” said Mr. Nelson Wong, Founder and CEO of CSI Medical Research, “CSI’s vision and mission in the approach to manage clinical trials are very much aligned with ClinChoice, and the company’s high-quality, efficiency and teamwork culture will be fantastic for our talented employees and clients alike. We are very looking forward to what we can achieve together.”

Read also – NoahArk Tech Group Secures $2.4M Investment From ENV

About ClinChoice

Founded in 1995, ClinChoice is a full-service global clinical CRO dedicated to offering high-quality, efficient and flexible solutions to pharmaceutical, biotechnology, medical device, and consumer products clients worldwide. With a 25 year history of success, ClinChoice continues to be The Standard of Excellence for biostatistics, clinical operations, data management, statistical programming, CDISC, regulatory affairs, medical affairs and pharmacovigilance.

Read also – anecdotes Secures $25 Mn Series B Funding

ClinChoice has established major delivery centers across US, China, Europe, Canada, India, Japan and the Philippines. It has over 4,000 employees globally, with a strong and talented team, and a growing clinical operations presence in seven countries across Asia, North America and Europe.

Read also – Delinea Acquires Authomize to Detect and Mitigate Identity Threats

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular